A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.
Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.
The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.
ASI has teamed up with Chromatan in order to deliver single-use and column-free capture purification services which could save clients 65% in chromatography costs in clinical manufacturing.
The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.
Detailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
The biomanufacturing industry needs to adopt an integrated approach to upstream and downstream processing to boost efficiency and productivity according to EMD Millipore.
SAFC Pharma is preparing for the shift towards cell culture-based vaccines, while still supplying and growing in the traditional sector, to ensure it can grow in coming years, according to a company director.
SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.
